ADC Therapeutics received accelerated approval for its drug from the FDA.
7 reports, 1 independent
Updated Sep 3
Gone quiet
- Reports
- 7
- Developments
- 1
- Repetition
- 86%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ADC Therapeutics received accelerated approval for its drug from the FDA.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.Also in this story
- Astex Pharmaceuticals and Newcastle University formed a strategic alliance with Hoffmann-La Roche to license breast cancer compounds.
- Hutchison MediPharma and AstraZeneca are jointly developing savolitinib TKI, with clinical data presentations scheduled for WCLC 2025 and CSCO Annual Meeting 2025.
The entities involved
-
ADC Therapeutics
company in Épalinges, Switzerland
Nothing else this week.
- FDA
Related events
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- The FDA recommended advancement for a new drug application submitted by a company.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- The FDA indicated on June 25, 2025, that an Advisory Committee (AdCom) was not necessary for a specific review.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
Coverage
Newest first; wire copies grouped- PR NewswireADC Therapeutics Makes Grants to New Employees Under Inducement Plan LAUSANNE, Switzerland, Sept. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pionee
- PR NewswireADC Therapeutics to Present at the Cantor Global Healthcare Conference 2025 LAUSANNE, Switzerland, Aug. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and
- PR NewswireADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-st
- PR NewswireADC Therapeutics Makes Grants to New Employees Under Inducement Plan LAUSANNE, Switzerland, Aug. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer
- Unknown outlet